Acadia Pharmaceuticals (ACAD) Finished Goods (2016 - 2026)

Acadia Pharmaceuticals' Finished Goods history runs 11 years deep, the most recent figure standing at $33.2 million for Q1 2026.

• In Q1 2026, Finished Goods rose 39.0% year-over-year to $33.2 million; the TTM figure through Mar 2026 stood at $33.2 million (up 39.0% YoY), while the FY2025 annual figure was $26.0 million, up 26.84% from the prior year.
• Finished Goods for Q1 2026 stood at $33.2 million, up from $26.0 million in the prior quarter.
• The five-year high for Finished Goods was $33.2 million in Q1 2026, with the low at $1.6 million in Q1 2023.
• The 5-year median for Finished Goods is $7.6 million (2024), against an average of $12.7 million.
• The sharpest annual moves came in 2023 and 2024: Finished Goods retreated 7.75% in 2023, then soared 758.53% in 2024.
• Acadia Pharmaceuticals' Finished Goods stood at $1.9 million in 2022, then surged by 159.66% to $5.0 million in 2023, then soared by 309.14% to $20.5 million in 2024, then climbed by 26.84% to $26.0 million in 2025, then rose by 27.81% to $33.2 million in 2026.
• Business Quant data shows ACAD's Finished Goods at $33.2 million in Q1 2026, $26.0 million in Q4 2025, and $25.0 million in Q3 2025.